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Abstract
Background: Monoclonal antibodies (mAb) against GD2 ganglioside have been shown to be effective for the treatment of
neuroblastoma. Beneficial actions are, however, associated with generalized pain due to the binding of anti- GD2 mAbs to
peripheral nerve fibers followed by complement activation. Neuroblastoma cells that express GD2 also express its O-acetyl
derivative, O-acetyl- GD2 ganglioside (OAcGD2). Hence, we investigated the distribution of OAcGD2 in human tissues using
mAb 8B6 to study the cross-reactivity of mAb 8B6 with human tissues.
Methodology/Principal Findings: The distribution of OAcGD2 was performed in normal and malignant tissues using an
immunoperoxydase technique. Anti-tumor properties of mAb 8B6 were studied in vitro and in vivo in a transplanted tumor
model in mice. We found that OAcGD2 is not expressed by peripheral nerve fibers. Furthermore, we demonstrated that mAb
8B6 was very effective in the in vitro and in vivo suppression of the growth of tumor cells. Importantly, mAb 8B6 anti-tumor
efficacy was comparable to that of mAb 14G2a specific to GD2.
Conclusion/Significance: Development of therapeutic antibodies specific to OAcGD2 may offer treatment options with
reduced adverse side effects, thereby allowing dose escalation of antibodies.
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Introduction
Neuroblastoma is a cancer of the sympathetic nervous system
that is responsible for 12% of deaths associated with cancer in
children under 15 years of age [1]. Despite advances in the
treatment of low- to intermediate-risk neuroblastoma, outcomes
for patients diagnosed with a high-risk phenotype characterized by
widespread dissemination of the cancer remains poor. Patients
undergo relapse and ultimately die from the tumor in spite of the
standard aggressive treatment, which includes surgery, radiation,
and/or myeloablative chemotherapy with stem cell rescue,
followed by 13-cis-retinoic acid [2]. Thus, once remission is
achieved, the major obstacle to a cure is residual chemotherapy-
refractory disease that eludes current methods of detection [3].
One of the most promising approaches for increasing the
efficiency of standard therapy in this case involves anti-ganglioside
GD2 immunotherapy [4]. GD2 ganglioside is an acidic glyco-
sphingolipid that is abundantly expressed on the cell surface of
tumor cells of neuroectodermic origin such as neuroblastoma [5].
In normal tissue, GD2 expression is largely limited to neurons, skin
melanocytes and peripheral nerve fibers [6,7], making it well
suited for targeted antitumor therapy. The rationale for passive
immunotherapy with anti-GD2 mAbs is supported by their anti-
tumor properties. Preclinical studies have shown that anti-GD2
mAbs may inhibit tumor cell growth via direct cell death induction
[8]. In addition, anti-GD2 mAbs can mediate tumor cell
destruction through antibody-dependent cellular cytotoxicity
(ADCC) and complement cell cytotoxicity (CDC) [9,10]. Inter-
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th in priority of all
clinical antigens by an NCI workshop [11].
Several anti-GD2 antibodies have been developed for clinical
use over the past 2 decades, two of which are under evaluation in
the clinical setting: ch14.18 [4] and 3F8 [12]. 3F8 is a completely
murine antibody and ch14.18 is a human–mouse chimeric
construct consisting of variable regions derived from the murine
anti-GD2 antibody 14G2a and of constant regions of heavy and
light chains from a human IgG1 molecule. A recent phase III trial
has shown that a combination of anti-GD2 ch14.18 antibody and
cytokines with the standard therapy significantly improved
outcome [4]. Although these results are very encouraging, one
of the major drawbacks of anti-GD2 mAbs is their toxicity. The
infusion is frequently associated with severe pain, changes in
cardiovascular tone, fever and complement depletion [13,14].
Furthermore subsequent to treatment with anti-GD2 monoclonal
antibody some patients have developed sensorimotor polyneurop-
athy [15]. These neurotoxic toxicities are most likely the result of
mAb recognition of GD2 on pituitary gland and peripheral nerves
and complement activation [6]. Hence, they limit the dose of anti-
GD2 mAbs that can be given and therefore its clinical efficacy.
In an effort to increase the therapeutic index of ch14.18, a
humanized antibody was recently designed in which the Fc region
was mutated in the CH2 domain to no longer engage C1q. The
resultant antibody, hu14.18 K322A, retained potent ADCC
activity against GD2-expressing tumor with impaired complement
activation in vitro, and, reduced neurotoxic side effects in rat [16].
However, since it still retains its binding activity to peripheral
nerve fibers, this format would not be suitable for developing
immunotherapeutic agents by conjugation to toxins, radionuclides
or other effector molecules.
In our laboratory, several anti-disialo-gangliosides antibodies
have been generated that recognize GD2, GD3 and acetylated
GD2 and GD3. One of these antibodies, mAb 8B6, was shown to
be specific for the O-acetylated derivative of GD2 (OAcGD2) with
no cross-reaction with GD2 [17] by thin layer chromatography
(TLC) immunostaining. OAcGD2 is concomitantly expressed by
GD2-positive tumor cells [18,19]. This antibody, mAb 8B6, was
not found to cross react with GD3, acetylated GD3 or other
gangliosides [17]. This prompted us to investigate the distribution
of OAcGD2 in human tissues. In contrast to GD2, OAcGD2 is not
expressed by human peripheral nerve fibers, suggesting that anti-
OAcGD2 8B6 antibody has the potential to be less toxic than anti-
GD2 therapeutic antibodies. In addition, mAb 8B6 is able to
inhibit tumor cells growth in vitro and in vivo. Interestingly, the
anti-tumor activity is comparable to anti-GD2 mAb 14G2a. These
results highlight the use of antibodies that target specifically
OAcGD2 to avoid the side effects of mAbs to GD2 in patients.
Results
Reactivity of mAb 8B6 with peripheral nerves and other
different normal tissues
Peripheral Nerves.. Binding of mAbs specific for GD2 to
peripheral nerves with subsequent activation of the complement
cascade is suspected to induce toxic effects when they are
administrated in patients. This prompted us to study the
reactivity of anti-OAcGD2 mAb 8B6 against peripheral nerves
with an immunoperoxydase technique. Example of results
obtained on peripheral nerves and neuroblastomas are shown
in Fig. 1 B.2. When anti-OAcGD2 mAb 8B6 was tested on all of
the 12 different samples, no labeling was present. Axons were
negative. By contrast, the sections of all the 12 different samples
stained with anti-GD2 mAb 14G2a showed strong positive
staining of the nerve fibers as shown in Fig. 1-B.3. The mouse
isotype control antibody was also negative (Fig. 1 B.1). These
data show that mAb 8B6 do not bind to peripheral nerves and
suggest that antibodies specific to OAcGD2 may offer new
treatment options with reduced adverse side-effect compared to
anti-GD2 mAbs. Five other representative results are depicted in
Fig. S1.
Other Normal Tissues. We next evaluated the reactivity
with other human tissues. Table 1 summarizes the reaction pattern
obtained when mAb 8B6 was tested against the 32 normal tissues
recommended by the FDA. Peripheral blood erythrocytes and
leukocytes, bladder, breast, brain cortex, fallopian tube, eye, heart,
liver, pituitary (Fig. S2), ovary, pancreas, prostatic epithelium, skin,
spleen, testis, thymus, ureter, vascular endothelium and smooth
muscle, nerves, and uterine cervix, endometrium, and myometrium
tissues were all negative. In the adrenal, the zona glomerulosa and
fasciculata were negative while the zona reticularis showed faint
cytoplasmic staining and moderate granular intracellular staining
(Fig. S2). There was also slight reactivity with Purkinje cells and the
Bergmann glia in the cerebellum (Fig. S2). Antibody 8B6 reacted
with lymph node germinal center cells (Fig. S2). In the bone
marrow, antibody 8B6 did not show any binding to the erythroid,
myeloid, and megakaryocyte series. Occasional macrophages
showed moderate granular cytoplasmic staining (Fig. S2). Anti-
body 8B6 also reacted faintly with the dorsal horns in the spinal
cord, and subsets of thyroid follicular epithelial cells (Fig. S2). These
data indicated that mAb 8B6 presents a very interesting safety
reactivity profile for its clinical use.
Tumor tissues. OAcGD2 was originally isolated from
neuroectodermic tumors such as neuroblastoma and melanoma
[18,19]. We, therefore, studied the binding activity of mAb 8B6 to
several human malignant tissues (Table 2). Table 2 summaries
mAb 8B6 immunoreactivity on tumor samples. As mentioned
above, an example of neuroblastoma tumor section stained by
mAb 8B6 is shown in Fig. 1. Other examples of neuroblastomas
are depicted in Fig. S3 and other OAcGD2-expressing tumors are
shown in Fig. S4. By IHC analysis, mAb 8B6 bound to 12/12
neuroblastomas, 3/4 small cell lung carcinoma and 3/4
melanomas. In positive tumors, 100% of tumor cells in
neuroblastomas were stained (Fig. S3), 75% for small cell lung
carcinomas, and 50% for melanomas. Staining was strongly
membranous and also faintly cytoplasmic (Fig. S4). Tumor tissues
from patients with pancreatic carcinomas (n=5) were negative.
Ganglioside OAcGD2 expression was also evidenced in the human
IMR32 neuroblastoma passaged in nude mice, the mouse EL4 T-
lymphoma grafted in C57Bl/6 mice, and the mouse NXS2
neuroblastoma grafted in A/J mice (data not shown).
Binding of mAb 8B6 to GD2-expressing cell line
Several groups have shown that tumor cells that express GD2
ganglioside also express OAcGD2 [18,19,20]. The extent to which
mAb 8B6 reacted with several types of human and mouse tumor
cell lines was determined by flow cytometry analysis. All cell types
that expressed GD2 ganglioside were found to also express
OAcGD2. These data were confirmed by analysis of the tumor cell
ganglioside content by immuno-thin-layer chromatography using
mAbs 8B6 and 14G2a (data not shown). It should be noted that in
these experiments, mAb 14G2a showed a slight cross reactivity
against OAcGD2 in agreement with a previous report [18]. We
next calculated the number of OAcGD2 molecules and of 14G2a’s
epitopes present at the cell surface by Scatchard analysis using
125I-labeled mAb 8B6 and
125I-labeled mAb 14G2a respectively.
As summarized in Table 3, cell lines revealed different levels in the
number of mAb binding sites. EL4, NXS2 and IMR32 cell lines
Anti-Tumor Antibody Specific for O-Acetyl-GD2
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numbers ranging from 0.5610
6 to 5.5610
6 sites/cell. The amount
of 14G2a binding sites was found to be comparable with 0.7610
6
sites/EL4 cell, 5.3610
6 sites/NXS2 cell and 12610
6 sites/IMR32
cell. The H82 cell line showed an intermediary binding site
number of 0.1610
6 sites/cell for OAcGD2 and GD2. The
OVCAR-3 and U87MG cells showed less than 5610
4 sites/cell,
whereas Neuro2a cells express neither OAcGD2 nor GD2
ganglioside. These data confirm the overexpression at the cell
surface of ganglioside OAcGD2 on numerous GD2-expressing
tumor cell lines. The affinity constants of mAbs 8B6 and 14G2a
were also calculated. The KD value of mAb 8B6 for OAcGD2 was
found to be 32 nM and of mAb 14G2a’s KD value for GD2 was
calculated to be 49 nM.
Reduction of tumor cell viability in vitro
Since in vitro cell culture experiments have shown that various
anti-GD2 mAbs inhibit tumor cell growth by directly inducing
apoptosis [8,21,22], we studied whether the mAb 8B6 displayed
the same effects on tumor cell viability. To test for the antitumor
activity of mAb 8B6, we choose the EL4 cell line because it is
tumorigenic in syngeneic immunocompetent C57Bl/6 mice and
because it was used previously in many preclinical studies with
anti-GD2 mAbs [23]. Cells were incubated with either mAb 8B6
or mAb 14G2a over a period of 72 hours. Cell viability was
determined by MTT assay. The control 4F6 antibody and the
Neuro 2a cell line were included to ensure that the observed result
was antigen-specific. The inhibitory effect on EL4 cell viability of
both mAbs 8B6 and 14G2a was dose- and time-dependant (data
not shown) and became statistically significant at 24 hours post
treatment at 20 mg/ml (p,0.01) when compared to mAb 4F6-
treated cells (Fig 2A). As expected, neither mAb 8B6 nor mAb
14G2a suppressed the growth of the antigen-negative Neuro 2a
cell line (data not shown). Overall, these results show the ability of
mAb 8B6 to inhibit tumor cell viability, independently of
immunological mechanisms such as CDC and ADCC.
Figure 1. Expression of OAcGD2 and GD2 ganglioside antigens on peripheral nerves and neuroblastomas. An immunoperoxydase
assay was performed as described in Material and Methods. Strong immunostaining was detected on neuroblastoma cells (A) with either mAb 8B6 (2)
or mAb 14G2a (3). No staining was observed on peripheral nerves (B) with mAb 8B6 specific for OAcGD2 (2). Myelin sheaths in the peripheral nerves
(B) were strongly stained with mAb 14G2a against GD2 (3). The mouse IgG3 mAb negative control from AbD serotec (Oxford, UK) was used as a
negative control (1). Scale bar =50 mm.
doi:10.1371/journal.pone.0025220.g001
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To test the ability of both mAbs to induce programmed cell
death, we stained antigen-expressing tumor cells with Apo2.7
antibody, followed by flow cytometry analyses, and compared
results to control 4F6 antibody-treated cells. Apoptotic cells were
detected by flow cytometric analysis after staining bound mAbs to
either GD2 or OAcGD2 with a FITC-conjugated goat anti-mouse
IgG F(ab’)2 fragment goat anti-mouse IgG. This analysis dif-
ferentiates the antigen expressing cells from the apoptotic one. As
shown in Fig. 2B, addition of either mAb 8B6 or mAb 14G2a to
the EL4 culture medium resulted in an increased percentage of
double-positive cells. Encouragingly, the effects of mAb 8B6 and
mAb 14G2a were comparable with about 75% of antigen-positive
cells undergoing apoptosis. The above finding was confirmed by
fluorescence microscopy of EL4 cells after Hoechst 33342 staining.
Microscopic analysis clearly showed bright nuclear staining and
highly condensed nuclei with condensed and fragmented chro-
matin induced by treatment with either mAb 8B6 or mAb 14G2a
(data not shown). These results show the ability of mAb 8B6 to
induce apoptosis in OAcGD2–expressing cell lines similarly to
mAb 14G2a specific for GD2.
Antibody induced ADCC and CDC
The capacity mAb 8B6 or mAb 14G2a to induce CDC and
ADCC with EL4 cells in the presence of A-LACK cells and
complement from C56BL/6 mice was next evaluated. For CDC
assays, the OAcGD2/GD2-expressing target cells were incubated
with mAb 14G2a in the presence of diluted mouse serum as
complement. Cell death was assessed by the addition of the
Table 1. OAcGD2 expression on normal tissues defined by
immunohistology*.
Tissue
mAb 8B6 binding to frozen tissue
sections
Adrenal Negative
{
Bladder Negative
Blood Cells Negative
Bone Marrow Negative
I
Brain, Cerebellum Negative
{
Brain, Cortex Negative
Breast Negative
Colon Negative
Endothelium Negative
Eye Negative
Fallopian Tube Negative
Gastroinstestinal Tract Negative
1
Heart Negative
Kidney, Cortex and Medulla Negative
Liver Negative
Lung Negative
Lymph Node Negative
II
Ovary Negative
Pancreas Negative
Parathyroid Negative
Pituitary Negative
Placenta Negative
Prostate Negative
Skeletal Muscle Negative
Skin Negative
Spinal Cord Negative
**
Spleen Negative
Testis Negative
Thymus Negative
Thyroid Negative
{{
Ureter Negative
Uteris, Cervix Negative
Uterus, endometrium
*Determined by immunoperoxydase assay using mAb 8B6 as described in
Material and Methods. The number of each tissue section tested ranged from 2
to 3.
{The zona reticularis showed faint cytoplasmic staining and moderate granular
intracellular staining;
IOccasional macrophages were positive
{the Purkinje Neurons were faintly positive;
1the epithelium apical surface showed staining similar to that of the isotype
control antibody;
II;the germinal centers of lymphoid follicles showed moderate to strong
stainning;
**the gray matter in the dorsal horns showed moderate staining;
{{the follicular epithelium showed faint cytoplasmic staining.
doi:10.1371/journal.pone.0025220.t001
Table 2. Presence of OAcGD2 in human tumors determined
by immunoperoxydase assays*.
Tumor tissue
# of positive tumor
tissues / # of tumor
tissues tested
% of positive cells in
OAcGD2-positive
tumors
Neuroblastoma 12/12 100%
Melanoma 3/4 50%
Small Cell Lung
Carcinoma
3/4 75%
Renal Carcinoma 1/3 33%
Ovarian Carcinoma 0/5 0%
Pancreatic Carcinoma 0/5 0%
*Using mAb 8B6 as described in Material and Methods.
doi:10.1371/journal.pone.0025220.t002
Table 3. Binding properties of mAbs 8B6 and 14G2a on
tumor cell lines*.
Origin Cell line
OAcGD2
expression
(610
6 /cell)
GD2
expression
(610
6 /cell)
Human
Neuroblastoma IMR32 5.5 12.6
Small cell lung carcinoma NCI-H69 0.16 0.19
Ovarina carcinoma OVCAR-3 0.02 0.04
Mouse
T lymphoma EL4 0.53 0.74
Neuroblastoma NXS2 0.52 1.3
Neuro 2a 0 0
*Determined by Scatchard analyses using
125I-labelled mAb 8B6 or
125I-labelled
mAb 14G2a.
doi:10.1371/journal.pone.0025220.t003
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mAb 8B6 nor mAb 14G2a mediated CDC on EL4 cells in the
presence of C57BL/6 mouse complement (Fig. 3A). This result
was not surprising because EL4 cell express the rodent inhibitor of
complement activation Crry that protects EL4 cells from
complement deposition [10]. Therefore, mAb 8B6 CDC testing
was performed with the NXS2 cells. By contrast to EL4 cells, an
efficient CDC was observed when NXS2 cells were used (Fig. 3B).
Specific lysis achieved maximum values of 36.861.4% when mAb
14G2a was used but only 18.861.9% with mAb 8B6. Cytotoxicity
correlated directly with the concentration of antibody. Specificity
was demonstrated by comparing the CDC results of mAb 8B6 and
mAb 14G2a with non-specific controls using anti-GD3 mAb,
which showed only background lysis. Specificity was also
demonstrated with the OAcGD2/GD2 negative Neuro 2A cells
where both mAb 8B6 and 14G2a were ineffective in activating
complement dependant cytotoxicity (Fig. 3C).
For ADCC reactions, the A-LAK cells generated from C57BL/
6 mice were composed by ,80% of CD3-negative, NK1.1-
positive NK cells and ,20% of CD3-positive, NK1.1-positive
NKT cells and the two populations expressed the Fcgamma RIII
receptor (data not shown). The target cells were labeled with a
membrane dye, PKH-26, to allow discrimination when incubated
with effector cells and antibody. Post-incubation, cell death within
the PKH-26 + target cell population was detected by the addition
of the viability probe TP3.
ADCC was observed with both mAb 8B6 and mAb 14G2a
against OAcGD2/GD2-expressing target cells when C57BL/6
mice A-LACK cells were used (Fig. 4A). However, mAb 14G2a
induced a more effective ADCC than mAb 8B6 with specific lysis
achieved maximum values of 29.561.4% with mAb 14G2a, but
only 11.562% with mAb 8B6 (Fig. 4A). This result was also
unsurprising since earlier works reported that mouse IgG3 mAbs
against ganglioside antigens are poorly effective in vitro in inducing
CDC and ADCC with mouse complement and mouse effector
cells [24,25]. On the other hand, EL4 cells were efficiently killed
when human NK effector cells were used with a maximum value
of specific lysis of 30% (Fig. S5). Cytotoxicity correlated directly
with the E/T ratio (Fig. 4A) and the antibody concentration
(Fig. 4D). The A-LAK killer efficiency was demonstrated with the
sensitive YAK-1 cells where specific lysis reached maximum value
of 51.461% (Fig. 4B). Specificity was demonstrated by comparing
the ADCC results of mAb 8B6 and mAb 14G2a with non-specific
controls using anti-GD3 mAb, which showed only background
lysis (Fig. 4A). Specificity was also demonstrated with the
OAcGD2/GD2 negative Neuro 2A cells where both mAb 8B6
and 14G2a were ineffective in activating complement dependant
cytotoxicity (Fig. 4C).
Analysis of in vivo antibody antitumor activity
We next evaluated whether mAb 8B6 could be used to treat
transplanted tumor. To determine if the OAcGD2 mAb 8B6 can
suppress tumor formation, we injected the EL4 syngeneic T-
lymphoma to C57BL/6 mice. Twenty four hours after tumor
inoculation, groups of 10 mice received 70 mg per dose of mAb
8B6, mAb 14G2a, irrelevant mAb, or PBS twice a week for 3
weeks. After tumor injection, we monitored the tumor volume and
the health of the mice. We measured the tumors biweekly and
euthanized the mice when their tumor size exceeded 2,000 mm
3.
The survival curves were plotted according to the Kaplan-Meier
method and compared using the log-rank test. The results are
summarized in Fig. 5. In the vehicle-treated group and in the
irrelevant antibody-treated group all animals developed large
tumors that were detected within 2 weeks after the initial
inoculation, and had died by day 42. In contrast, 60% of the
mice that had received mAb 8B6 were still tumor free after 90 days
and were considered cured. In comparison, 70% of the mice were
still tumor free in the mAb 14G2a treated group. The effect of
mAb 8B6 treatment was not statistically different from that
obtained upon treatment with mAb 14G2a (p,0.05). The
Figure 2. Antibody 8B6 and mAb 14G2a each induce viability inhibition and apoptosis of EL4 cells. (A), EL4 cell line was treated for 24
hours with various concentrations of mAb 8B6 (N), mAb 14G2a (&) and a control 4F6 antibody (m). Viability was assessed as described in « Materials
and Methods » by adding the methylthiazole tetrazolium salt during 4 hours (MTT assay). Optical density was recorded at 570 nm. The data are
presented as the mean 6 SD for three independent experiments, each in triplicate. (B), On the treated right column, EL4 cells were exposed to either
50 mg/mL of mAb 8B6 or mAb 14G2a for 24 hours and then double stained with fluorescein-isothiocyanate-conjugated F(ab’)2 fragments of goat anti-
mouse IgG (H+L). After permeabilization, cells were stained with Apo2.7-PE antibody as described in "Materials and Methods". The percentage of
double-positive cell in the untreated EL4 tumor cells is indicated in the left column. Numbers in quadrants represent the percentage of cells in each
section of the quadrant.
doi:10.1371/journal.pone.0025220.g002
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with an equivalent amount of non-specific IgG3 antibody was
completely ineffective. Notably, this control antibody binds to
GD3 ganglioside that is not express by EL4 cells (data not shown).
The anti-neuroblastoma efficacy of mAb 8B6 was also
determined in the NXS2 mouse neuroblastoma experimental
liver metastasis model developped by lode et al.[26] (Fig. S6). The
treatment of mice (n=9) at the dose of 100 mg mAb 8B6/day for 5
days was dramatically effective in reducing neuroblastoma liver
metastasis, as indicated by a decrease of the liver weight from 2.8
g60.8 g (PBS) to 1.2 g60.8 g (mAb 8B6 treated mice) and
1.1 g60.2 g mAb 14G2a (p,0.001) (Fig. S5.A). The latter two
values were not statistically different from those found in healthy
control animals (p.0.1). The effect of mAb 8B6 treatment was not
statistically different from that obtained upon treatment with mAb
14G2a (p.0.5). The specificity of mAb 8B6 therapy was again
demonstrated, since treatment with an equivalent amount of non-
specific antibody was completely ineffective. Taken together, our
results show the potential therapeutic efficacy of mAb 8B6 for the
treatment of GD2/OAcGD2-expressing tumors.
Discussion
The most striking result of this study is that mAb 8B6, a mouse
monoclonal antibody specific for OAcGD2 that does not bind
GD2, did not show any reactivity at all with peripheral nerves. By
contrast, the anti-GD2 antibody 14G2a that was used as a positive
control stained peripheral nerve fibers, which are known to express
GD2 [6]. In these study, we selected an immunoperoxydase assay
performed on frozen tissue sections according to the FDA
guidelines [27]. In the absence of characterization of the O-
acetyl-transferase, the enzyme responsible for the biosynthesis of
O-acetylated ganglioside (for review see [28]), the results suggest
that GD2 is differentially acetylated in normal and tumor tissue
and that normal tissues expressing GD2 may not express
OAcGD2, as is known for GD3 (for a review see [29]). Antibody
8B6 did not stain or stain very weakly the normal tissues that must
be tested before clinical tested, as required by the FDA, with the
exception of lymph node germinal centers. This exception may be
considered as a positive control for the ICH study since GD2 has
been shown to be expressed in lymph node germinal centers [7].
As mentioned earlier, the therapeutic use of anti-GD2 mAbs is
associated with important neurotoxic effects in patients. The
proposed cause of this dose-limiting toxicity is the binding of anti-
GD2 antibodies to GD2 expressed on normal nerve cells followed
by complement deposition on the nerve cell surface [6]. Hence,
our data suggest that mAbs specific for OAcGD2 should be less
toxic because they do not bind to peripheral nerves, thereby
allowing dose escalation of antibodies. Some other side effects
observed in patients after anti-GD2 mAb infusions included
hematopoietic suppression [30] and a syndrome of inappropriate
antidiuretic hormone [6]. The immune recognition of GD2 on
mesenchymal stromal cells in the marrow microenvironment was
suggested to underlie the hematopoietic suppression and anti-GD2
mAb cross-reactivity with the posterior lobe of the pituitary gland
is believed to modulate the secretion of antidiuretic hormone
resulting in the induction of the syndrome of inappropriate
antidiuretic hormone secretion[6]. Interestingly, mAb 8B6 did not
show any binding to mesenchymal stromal cells in the bone
narrow nor to the posterior lobe of the pituitary gland. We also
examined the immunohistochemical OAcGD2 localization in a
number of malignant tissues and found that mAb 8B6 showed
strong reactivity with neuroectodermic tumor biopsy tissues, such
as melanoma and neuroblastoma similar to previous investigations
[18,19].
We further demonstrated the high expression of OAcGD2 at the
tumor cell surface by Scatchard analysis in vitro. In the 7 tested cell
lines, the average of sites/cell ranged from 50,000 sites/cell up to
5610
6 sites/cell. The expression level of OAcGD2 in cell lines was
first described based on extraction and thin layer chromatography
(TLC) or immune TLC [18,19]. These methods cannot
discriminate the membrane from intracellular OAcGD2 cell
content. Importantly, our data shows that the amount of OAcGD2
Figure 3. Activation of complement by mAb 8B6 and mAb
14G2a. Complement-dependent specific lysis was determined for the
EL4 cell line (A), the NXS2 cell line (B), and the OAcGD2/GD2-negative
Neuro 2A cells (C) as described in Material and Methods. Empty
columns, irrelevant antibody; black columns, mAb 8B6; grey columns,
mAb 14G2a.
doi:10.1371/journal.pone.0025220.g003
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to that of mAb 14G2a epitope. However, the number of GD2
molecules calculated here may be overestimated as previous
reports suggested that mAb 14G2a cross-reacts with OAcGD2
[18]. In agreement with this earlier study, we did see a slight cross-
reactivity of mAb 14G2a against OAcGD2 in immuno-TLC
experiments (data not shown). Scatchard analysis further showed
that mAb 8B6 and mAb 14G2a displayed equivalent binding
affinities for their respective epitopes that were within the range
anti-GD2 antibodies [21,24,31,32]. OAcGD2 expression was
confirmed on all of the 12 neuroblastoma tumor sections tested.
This is consistent with a previous study reported by Ye and
Cheung [19] that OAcGD2 is a naturally occurring GD2
derivative in neuroblastoma tumors.
We also showed that OAcGD2 is a pro-apoptotic constituent
activated on binding with hostile antibodies. Despite its high
expression at the tumor cell surface, the biological role of OAcGD2
has yet not been studied so far. The results presented here
demonstrate that OAcGD2 behaves very similarly to GD2 in
mediating apoptosis in the GD2/OAcGD2-expressing tumor cells
Figure 4. ADCC of mAb 8B6 and mAb 14G2a. (A) The A-LAK killer activity with mAb 8B6 and mAb 14G2a with EL4 target cells at the E/T ratio 12
to 1 (empty columns), 25 to 1 (grey columns), and at the E/T ratio 50 to 1 (black columns) as described in Material and Methods. (B) The A-LAK killer
efficiency in the ADCC assays was tested using the sensitive YAC-1 target cells. (C) ADCC activity with mAb 8B6 and mAb 14G2a against the OAcGD2/
GD2-negative Neuro 2A cells used as a negative control, at the E/T ratio 12 to 1 (empty columns), 25 to 1 (grey columns), and at the E/T ratio 50 to 1
(black columns). (D) ADCC mediated by mAb 8B6 (grey column) and mAb 14G2a (black column) with EL4 target cells at varying antibody
concentrations. The results were compared to the effect of equal amount of irrelevant antibody used as a negative control (n=3).
doi:10.1371/journal.pone.0025220.g004
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cell biology. O-Acetylation of GD3 prevents apoptosis in lymphoid
cells induced by various agents—including GD3 itself—and
therefore sustains tumor progression [33,34]. While OAcGD2
can transmit signals resulting in apoptosis, the precise mechanisms
induced by the binding of OAcGD2 antibody to OAcGD2-
expressing tumor cells leading to apoptosis requires further
investigation. In the case of GD2, initial indications suggest that
anti-GD2 mAbs induce apoptosis of SCLC cells by interfering
with the association of GD2 ganglioside to ß1-integrin and focal
adhesion kinase [35]. The OAcGD2-triggered apoptosis may
follow the same pathway, for the ß1-integrin binding site to GD2
might exclude the outer sialic acid that becomes O-acetylated in
OAcGD2. However, since the addition of an O-acetyl ester to sialic
acid changes its structural properties and affects its binding
specificity, the association between OAcGD2 and integrin remains
open.
Finally, we reported for the first time that passive immunother-
apy with mAb 8B6 to OAcGD2 is effective in suppressing the
growth of OAcGD2-expressing tumor in two animal models. We
used the EL4 murine lymphoma that is syngeneic in C57BL/6
mice and the murine NXS2 neuroblastoma that is syngeneic in A/
J mice. These two cell lines express GD2 and as demonstrated here
OAcGD2. These two cell lines were retained because they were
previously used in the anti-GD2 antibodies preclinical setting
[9,23]. Our results further demonstrate that the anti-tumor
efficacy of mAb 8B6 is comparable to that of anti-GD2 mAb
14G2a, which has undergone clinical evaluation with positive
results [14,15,36]. Antibody 14G2a is also the parental mouse
antibody of human-mouse chimeric ch14.18 that has recently
shown clinical efficacy in a phase III trial [4]. ADCC has been
proposed as the most critical effector function in vivo for mAbs
against GD2 gangliosides [9,10]. In our experiments we used mAb
8B6 which is a mouse IgG3. Despite past controversy about the
presence or the absence of a mouse IgG3 Fc-receptor, this isotype
is now well known for its inability to promote ADCC with mouse
effector cells both in vitro and as in vivo, as it barely binds to mouse
FcgammaRs [37,38]. Then, as expected, mAb 8B6 failed to show
any ADCC activity in the presence of mouse spleen cells, but was
effective in directing ADCC against EL4 cell line with human NK
cells. Moreover, our data indicate here that the EL4 cells used in
our experiments were resistant to mouse complement. This finding
is in agreement with Imai et al. [10], who have reported that EL4
cells express the rodent inhibitor of complement activation Crry
that inhibits complement activation at the C3 activation step,
protecting EL4 cells from complement deposition and lysis [10].
Interestingly, the absence of sensitivity to complement does not
appear to affect the anti-tumor effect of anti-GD2 mouse IgG
mAbs except at low antibody concentration in vivo [10]. The
absence of Fc-directed CDC/ADCC functions requirement for
anti-GD2 mAb anti-tumor efficacy in vivo was also suggested by
Mujoo et al. [24] who studied the anti-tumor properties of mouse
IgG3 mAb 14.18 and its isotype switch variants. In their study,
mAb 14.18 was demonstrated to be as effective as mAb 14G2a in
suppressing neuroblastoma growth in mice and no correlation
could be drawn between the in vivo anti-tumor effects of these
antibodies and their in vitro functions such as directing ADCC
and CDC [24].
In as much as mAb 8B6 directs neither ADCC nor CDC with
EL4 cells when mouse immune effectors are used, the mechanism
whereby it mediates in vivo suppression of tumor growth in this
model is also most likely to involve its pro-apoptotic properties.
Although the mechanism remains to be elucidated in vivo, from a
clinical standpoint, the apoptosis inducing activity of mAb 8B6
specific for OAcGD2 evidenced here seems very promising when
applied to cancer therapy. Additional biological processes after
antibody binding to tumor cells such as CDC and ADCC have
been demonstrated in vivo. However, pro-apoptotic properties
without immune effector mechanisms may be important in the
treatment of tumors that have evolved complex mechanisms to
protect themselves from ADCC and CDC. We are currently
generating a human-mouse chimeric anti-OAcGD2 IgG1 form
mAb 8B6 in order to better define the role of immune effector
mechanisms involved in the anti-tumor properties of anti-
OAcGD2 antibodies. Whatever the effector mechanism(s) in-
volved, our results strongly support the clinical use of anti-
OAcGD2 mAbs. In contrast to anti-GD2 therapeutic antibodies,
they may offer an effective treatment option with reduced adverse
side effects, thereby allowing dose escalation of antibodies, and the
development of more potent immunoconjugates such as immu-
notoxines or radio-conjugates and immunocytokines. In addition
to neuroblastoma, melanoma, OAcGD2 is also expressed on
osteosarcomas, ovarian carcinomas [18,19,20] and, as reported
here, on small cell lung carcinomas, suggesting that anti-OAcGD2
immunotherapy is applicable to all these types of cancers. In all,
OAcGD2-expressing diseases account for ,7% of all death in the
US [39].
Materials and Methods
Cell culture
Cell lines were obtained from the American Type Culture
Collection (ATCC), except for the mouse neuroblastoma NXS2
cell line which was a courtesy of Dr. H. N. Lode (Universita ¨tsklinikum
Greifswald, Greifswald, Germany) and the YAC-1 cells (courtesy of
B. Clemenceau, Inserm U. 892, Nantes, France). Murine T-
lymphoma EL4 cells were grown at 37uCi n5 %C O 2 in DMEM
with 10% heat-inactivated FCS, 100 units/mL penicillin, and
100 mg/mL streptomycin. Human neuroblastoma IMR32, human
glioma U87MG, human small cell lung cancer H82, human
ovarian adenocarcinoma OVCAR-3, murine lymphomaYAC-1,
and mouse neuroblastoma Neuro 2a cell lines were grown at 37uC
in 5% CO2 in RPMI 1640 with 10% heat-inactivated FCS,
100 units/mL penicillin, and 100 mg/mL streptomycin. The
mouse neuroblastoma NXS2 cell line was grown at 37uCi n5 %
Figure 5. Survival of C57BL/6 mice inoculated with EL4 cells
treated with either 8B6 or 14G2a mAb. Mice (n=10) were
inoculated with 10
4 EL4 cells subcutaneously and then treated with
either PBS or 70 mg of each antibody, twice weekly for 3 weeks. PBS (N),
mAb 8B6 (#), mAb 14G2a (,), control 4F6 antibody (%).
doi:10.1371/journal.pone.0025220.g005
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penicillin, and 100 mg/mL
Antibodies and serum
Anti-OAcGD2 mAb 8B6 (mouse IgG3, kappa) was obtained
previously in our laboratory [17]. An IgG3 antibody specific to
GD3 ganglioside (clone 4F6) was used as a negative control
(generously provided by Dr. Jacques Portoukalian, Department of
Dermatology, Edouard Herriot Hospital, University of Lyon,
France) [17]. Monoclonal antibodies 8B6 and 4F6 were purified
from hybridoma supernatants using Protein A affinity chroma-
tography. The purity of mAb preparations was verified by SDS-
PAGE analysis. Anti-disialoganglioside GD2 mAb 14G2a was
purchased from BD Biosciences (Franklin Lakes, NJ). The mouse
IgG3 mAb negative control from AbD serotec (Oxford, UK) was
used as a negative control in some experiments.
Human tissues reactivity of mAb 8B6
Portions of fresh peripheral nerves and malignant tissues were
provided by the Pathology department at the Centre Hospitalier
Universitaire, Nantes, France. Eight fragments of neuroblastoma
samples were provided by the Children’s Hospital Oakland
Research Institute Tissue Bank (Oakland, CA, USA). Fresh tissue
specimens were embedded in Tissue Tek-II O.C.T. (Miles,
Naperville, IL), snap frozen in isopentane in liquid nitrogen, and
stored at 270u C. Ten micrometer-sections were cut, fixed in
acetone, and stained with mAb 8B6 and mAb 14G2a respectively
for 1 hour. After rinsing, the APAAP complex (Dako) was applied.
Then, the bound mAb was detected with ImmPACT DAB
chromogen substrate solution (Vector Laboratories, Bulingore,
CA), which was used to produce a brown deposit. The mouse
IgG3 negative control reagent (AbD serotec) was used as a
negative control, and neuroblastomas were used as positive
control. The concentration of 2.5 mg/mL was selected for the
study. Slides were counter-stained with hematoxylin before
immunocytological evaluation. Staining was graded as positive
or negative according to the presence or absence of immunore-
activity, respectively.
The potential cross-reactivity of mAb 8B6 was also evaluated by
using an indirect immunoperoxydase assay on a panel of 32 tissues
from unrelated donors according to the FDA guidelines [27] and
on a panel of melanomas, small cell lung carcinomas, renal
carcinomas, ovarian carcinomas and pancreatic carcinomas. This
study was performed independently by Lifespan Biosciences
(Seattle, WA, USA). Tissues were stained with positive control
antibodies specific for CD31 and for vimentin to ensure that the
tissue antigens were preserved and accessible for immunohisto-
chemical analysis. Only tissues that were positive for CD31 and
vimentin staining were selected for mAb 8B6 immunoreactivity.
Anti-OAcGD2 8B6 mAb was used as the primary antibody, and
the principal detection system consisted of a Vector anti-mouse
secondary (Vector Laboratories), and a Vector ABC-AP kit
(Vector Laboratories) with a Vector Red substrate kit (Vector
laboratories), which was used to produce a fuchsia-colored deposit.
The mouse IgG3 negative control reagent (AbD serotec) was used
as a negative control. Slides were imaged with a DVC 1310C
digital camera coupled to a Nikon microscope. Images were stored
as TIFF files with Adobe Photoshop.
Flow-cytometric analysis
Cell surface OAcGD2- and GD2-expression on tumor cell lines
was assessed by indirect immunofluorescence. Tumor cells (56105
cells) were incubated with either mAb 8B6, mAb 14G2a or mAb
4F6 (control antibody), at 10 mg/mL for 30 minutes at 4uCi n
0.1% BSA-PBS. After reaction with the fluorescein-isothiocyanate-
conjugated F(ab’)2 fragment of goat anti-mouse IgG (H+L) as a
second antibody (Jackson, Immunoresearch, Soham, UK) for
30 min at 4uC, cell fluorescence was analyzed using a FACScan
flow cytometer (BD Biosciences, San Jose, CA) and CellQuest
software (BD Biosciences).
Scatchard analysis
Monoclonal antibodies were labeled with iodine-125 (Perkin
Elmer, Billerica, MA) using the iodogen method and were purified
on a Sephadex PD10 column (Pharmacia Biotech, Uppsala,
Sweden). Binding assays were performed as previously described
[40]. Serial dilutions of labeled antibody were incubated for
1 hour at 4uC with 1610
6 cells. Cell-bound radioactivity was
separated from free antibody by centrifugation through a dibutyl
phthalate oil cushion in microfuge tubes. Cell Pellets and
supernatant activities were then separately measured using a
gamma counter (Wallac, Finland). Nonspecific binding, defined as
the cell-bound
125I-labeled antibody in the presence of a 100-fold
excess of unlabelled antibody, was subtracted at each concentra-
tion of labeled antibody. The binding data were analyzed using the
Prism software (GraphPad Prism Software, La Jolla, CA)
according to a one-site equilibrium binding equation.
Cell growth inhibition
Cell viability was measured using the MTT assay [41]. Briefly,
1610
5 cells suspended in 200 mL were incubated for 24 hours at
37uC, 5% CO2. Monoclonal antibodies were diluted in 100 mLo f
specific medium and added to each well of 96-well microtiter
plates to give the final concentrations of 80, 60, 40, 20 and
10 mg/mL. After incubation for 24 hours at 37uC, 5% CO2,
10 mL of methylthiazole tetrazolium salt stock solution (5 mg/
mL, Sigma Aldrich, Saint Louis, MO) were added to each well
and the plates incubated at 37uC for 4 hours. Then, 100 mLo f
10% Triton X-100 were added and the plates incubated for 10
minutes at 37uC for color development. Optical density was
recorded at 570 nm on a Multiskan reader (Thermo Electron,
Walthman, MA).
Apoptosis induction
Cells (1610
5 cells) were plated in 96-well microplates during
24 hours at 37uC5 %C O 2 and then treated for 24 hours at 37uC
with 50 mg/mL of mAb 8B6, mAb 14G2a and control mAb,
respectively. After reaction, cells were incubated with fluorescein-
isothiocyanate-conjugated F(ab’)2 fragments of goat anti-mouse
IgG (Jackson) as described above. They were then permeabilized
with 100 mg/mL digitonin and stained for 30 min with Apo2.7-PE
conjugated antibody and analyzed by flow cytometry using a
FACScan flow cytometer and Flowjo6 software (BD Biosciences).
Apoptotic cells were analyzed on Apo2.7 (FL2) histograms and
compared to OAcGD2 positive and negative cell populations
determined by FITC staining (FL1).
Complement dependent cytotoxicity (CDC)
Aliquots of tumor cells (104 cells) were incubated with 80 mLo f
antibody at various concentration in the presence of 20 mLo f
mouse-serum as complement source for 1 hour at 37uC.
Cytotoxicity was determined within the tumor cell population
after addition of the viability probe propidium iodide (PI) using a
FACScan flow cytometer (BD Biosciences, San Jose, CA) and the
CellQuest software (BD Biosciences). The percentage of specific
lysis was calculated as: 1006(nonviable PI+ tumor cells)/(non
viable PI+ tumor cells + viable tumor cells).
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An ADCC assay was performed as reported previously [42].
Briefly, tumor cells were labeled with membrane dye PKH-26
(Sigma Aldrich) according to the manufacturer’s instructions.
Aliquots of the labeled cells were distributed into a 96-well
microtiter plate (16104 cells /100 mL) were incubated with 25 mL
of antibodies in 96-well microtiter plates. Adherent lymphokine-
activated killer (A-LACK) cells isolated from spleen cells of C57BL/
6 mice were used as effector cells [43]. Fifty mL of effector cell
suspensionattheindicatedeffector-to-target (E/T ratio)wereadded
to the tumor cells and incubated for 4 hours at 37uC. Cell death
within the PKH-26+ target cell population was then assessed by the
addition of TO-PRO-3 iodide (TP3) (Invitrogen) [44]. The double-
positive dead target cell population was detected by flow cytometry
analysis using a FACScan flow cytometer (BD Biosciences) and the
CellQuest software (BD Biosciences). The percentage of specific
lysis was calculated as: 1006(nonviable TP3+, PKH26+ double-
positive target cells)/(non viable double-positive target cells + viable
PKH26+ target cells). The lysis of the NK-sensitive mouse T cell
lymphoma YAC-1 was used as an indicator of A-LAK activity [45].
Murine tumor model
C57BL/6 mice, aged between 8 and 12 weeks, were purchased
from Charles River (L’Arbresle, France). Mice were housed at the
animal facility of Inserm U892 (Nantes, France). This facility is
approved by the French Association for Accreditation of Animal
Care Laboratories and is maintained in accordance with the
regulations and standards of Inserm Institute and the French
Department of Agriculture. The EL4 cell line is a syngeneic
murine lymphoma in C57BL/6 mice that was previously used by
Imai et al. as a target for anti-GD2 antibodies [10]. Mice were
injected subcutaneously with EL4 cells (1610
4 cells) in the right
flank. Twenty four hours after tumor inoculation, groups of 10
mice received 70 mg per dose of 8B6 mAb, 14G2a mAb, control
IgG3 mAb, or PBS twice a week for 3 weeks. Tumor volume and
the health of the mice were monitored. After grafts became visible,
the sizes of tumors were determined three times a week by
externally measuring the tumors in two dimensions. Tumor
volume was calculated according to the equation: V =( L6W
2)
60.5, where L is the length and W the width of a tumor [46]. For
ethical considerations, mice had to be euthanized once tumor
volume had reached 2,000 mm
3, which was considered the end
point for each individual mouse.
Statistical analysis
Statistical analysis was performed using Prism software
(GraphPad Prism Software). Data are shown as mean 6 standard
error. Differences between un-treated and treated groups in the in
vitro experiences were analyzed by Student’ t test with significance
at p,0.05.
Supporting Information
Figure S1 In Fig. S1, five other representative examples
of peripheral nerve stained by either anti-GD2 mAb
14G2a (1) or anti-OAcGD2 mAb 8B6 (2) are shown. While
positive staining of the myelin sheaths—evidenced by brown
coloration—is found in all sample stained with anti-GD2 mAb
14G2a, no binding of anti-OAcGD2 mAb 8B6 is detected. Scale
bar =50 mm.
(TIF)
Figure S2 The synopsis of mAb 8B6 cross-reactivity
with human normal tissues is provided in Table 1. In Fig.
S2, representative results of mAb 8B6 (1) human tissue cross-
reactivity with the zona reticularis of the adrenal (A), the germinal
center in the lymph node (B), the Purkinje cells in the brain
cerebellum (C), the epithelium apical surface of the small intestine
(D), the follicular epithelium in the thyroid (E), and the gray matter
in the dorsal horns (F) are shown. The tissue cross reactivity study
was performed using an immunoperoxydase assay as indicated in
the ‘‘Material and Methods’’ section. The mouse IgG3 mAb
negative control from AbD serotec (Oxford, UK) was used as a
negative control (2). Representative positive staining of mAb 8B6
on melanoma (1) representative negative staining of control IgG3
(2) on melanoma cells (G). Photos are reproduced with the
permission of Lifespan Biosciences. Magnification 4006.
(TIF)
Figure S3 While Table 2 summarize the expression of
OAcGD2 on human neuroblastoma tumors, Fig. S4
shows 8 representative examples of OAcGD2 expression
on neuroblastomas detected by an immunoperoxydase
assay performed with mAb 8B6 as described in the
Material and Methods Section. 1, representative positive
staining obtained with anti-GD2 mAb; 2, representative negative
staining obtained with the mouse IgG3 mAb negative control (AbD
Serotec); 3 to 10, representative diversity patterns from neuroblas-
toma samples. Antibody 8B6 showed moderate to strong positive
staining with all neuroblastomas. The percentage of tumor cells that
were positive was 100% and staining was both membranous and
cytoplasmic. When the corresponding normal cell types were
present in the same cancer samples, they were negative. All samples
were also positively stained with mAb 14G2a and negative with
irrelevant control mAb (data not shown). Scale bar =100 mm.
(TIF)
Figure S4 While Table 2 summarize the expression of
OAcGD2 on human tumor, in Fig. S4 representative
example of expression of mAb 8B6 epitope in melanoma
cells (A) and small cell lung carcinoma cells (C) are
shown. Skin (B) and lung (D) samples from control patients
without cancer showed negative staining in the precursor cell type.
The samples were stained with mAb 8B6 using an immunoper-
oxydase assay performed as described in the ‘‘Material and
Methods’’ section. The mouse IgG3 mAb negative control from
AbD serotec (Oxford, UK) was used as a negative control (data not
shown). Photos are reproduced with the permission of Lifespan
Biosciences. Magnification 4006.
(TIF)
Figure S5 While Fig. 4 shows that mAb 8B6 ADCC
activity against mouse EL4 target cells was poorly
effective with mouse effector cells, an efficient killer
activity of human NK cells with mAb 8B6 is depicted in
Fig. S5. ADCC assays were performed at the E/T ratio 50 to 1
using mAb 8B6 (10 mg/ml, black column). Antibody 8B6 specific
antibody-dependent lysis occurred in a dose-dependent fashion.
Specificity was demonstrated by comparing the ADCC results of
mAb 8B6 with non-specific controls using anti-GD3 mAb (10 mg/
ml, empty column), which did not show any significant activity,
n=3.
(TIF)
Figure S6 While Fig. 5 shows the anti-tumor efficacy of
mAb 8B6 against EL4 lymphoma cells in C57BL/6 mice,
the anti-neuroblastoma activity of mAb 8B6 against
established experimental liver metastasis are depicted
in Fig. S5. Mice (n =9) were inoculated with 0.25610
6 NXS2
cells by i.v. injection and then treated 3 days latter with 5 daily i.v.
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antibody. Mice were sacrificed 28 days after tumor cell
inoculation. (A) The liver weight was determined on fresh
specimen. The y-axis starts at 0.8 g corresponding to the average
normal liver weight. The differences in average liver weights
between experimental groups treated with mAb 8B6 and mAb
14G2a and all control groups (PBS, control antibody) was
statistically significant (*p ,0.001). (B) Representative liver
specimen of each experimental group (n=9) are shown. 1, PBS;
2, control IgG3, 3, mAb 8B6; 4, mAb 14G2a. Arrows indicate the
location of macroscopic liver metastases.
(TIF)
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